Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
About this item
Full title
Author / Creator
Publisher
Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to...
Alternative Titles
Full title
Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_futurescience_futuremedicine_10_2217_fvl_15_61
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_futurescience_futuremedicine_10_2217_fvl_15_61
Other Identifiers
ISSN
1746-0794
E-ISSN
1746-0808
DOI
10.2217/fvl.15.61
